Endocannabinoids in the central nervous system;Le système endocannabinoïde central

Medecine/Sciences

Volumn 20, Issue 1, 2004, Pages 45-53

  Venance, Laurent ^a   Maldonado, Raphael ^b   Manzoni, Olivier ^c  

^a l'alimentation et l'Environnement   (France)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADENYLATE CYCLASE; ANANDAMIDE; CALCIUM CHANNEL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; FOCAL ADHESION KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL; VANILLOID RECEPTOR 1;

BRAIN REGION; CENTRAL NERVOUS SYSTEM; HUMAN; ION CONDUCTANCE; NEUROTRANSMITTER RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CANNABIS;

EID: 1642460848     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200420145     Document Type: Review

References (54)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
2. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
4. Fride E. Endocannabinoids in the central nervous system-an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66: 221-33.
5. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolomides in the brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032-4.
6. Mechoulam R, Ben-Shabat S, Hanus L, et al. identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
7. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
8. Giuffrida R, Beltramo M, Piomelli D. Mechanism of endocannabinoid inactivation: biochemistry and pharmacology. J Pharm Exp Ther 2001; 298: 7-14.
9. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66: 101-21.
10. Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C. In cultured mouse astrocytes, but not in neurons, anandamide has pharmacological effects distincts from synthetic cannabinoids. Eur J Neurosci 1999; 11: 691-9.
11. Holler J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptors on anxiety. Eur J Neurosci 2002; 16: 395-8.
12. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66: 377-91.
13. Suguira T, Koyabashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiologicol significance. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66: 173-92.
14. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-48.
15. McAllister SD, Glass M. CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66: 161-71.
16. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMB0 J 2001; 20: 7033-40.
17. + channel TASK-I. EMB0 J 2001; 20: 47-54.
18. + M-current in hippocampal CA1 neurons. J. Neurosci 2000; 20: 51-8.
19. Venance L, Piomelli D, Glowinski J, Giaume C. Inhibition by anadamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 1995; 376: 590-4.
20. Venance L, Sagan S, Giaume C. R-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes. Eur J Physiol 1997; 434: 147-9.
21. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase regulation. Nat Med 2000; 6: 313-9.
22. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95: 175-84.
23. Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 2002; 5: 723-4.
24. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-82.
25. Kreitzer AC, Regehr WG. Retrograde signalling by endocannabinoids. Curr Opin Neurobiol 2002; 12: 324-30.
26. Llano I, Leresche N, Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 1991; 6: 565-74.
27. Pitler TA, Alger BE, Postsynaptic spike firing reduces synoptic GABAA responses in hippocampal pyramidal cells. J. Neurosci 1992; 12: 4122-32.
28. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synopses of the mouse nucleus accumbens. J Neurosci 2001; 21: 109-16.
29. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synoptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99: 8384-8.
30. Doherty J, Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 2003; 3: 46-53.
31. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 2002; 5: 446-51.
32. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4.
33. Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999; 10: 327-31.
34. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-78.
35. Ledent C, Valverde O, Cossu G, et al. Unresponsivenes to cannabinoids and feduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 15.
36. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
37. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998; 286: 1301-8.
38. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
39. Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 1999; 19: 6795-805.
40. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
41. Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999; 379: R1-R2
42. Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res 1998; 812: 270-4.
43. Chakrabarti A, Ekuta JE, Onaivi ES. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Res Bull 1998; 45: 67-74
44. 9-tetrahydrocannabinol. Psychopharmacology 2002; 163: 111-7.
45. Miczek KA. Delta9-tetrahydrocannabinol: Antiagressive effects in mice, rats, and squirrel monkeys. Science 1978; 199: 1459-61.
46. Rodriguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414: 209-12.
47. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95: 127-35.
48. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353: 560.
49. Jarvinen T, Pate DW, Laine K. Cannabinoids the treatment of glaucoma. Pharmacol Ther 2002; 95: 203-20.
50. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95: 185-90.
51. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseco. F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24.
52. Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia. Biochemical, therapeutic aspects. Pharmacol Ther 2002; 95: 137-52.
53. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: 165-74.
54. Van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002; 26: 317-46.